EN | UA
EN | UA

Help Support

Back

Apremilast vs. Methotrexate: Efficacy and tolerability for moderate-to-severe palmoplantar psoriasis

Palmoplantar psoriasis Palmoplantar psoriasis
Palmoplantar psoriasis Palmoplantar psoriasis

This randomized clinical trial sought to determine the tolerability and effectiveness of Apremilast and Methotrexate in individuals suffering from palmoplantar psoriasis.

See All

Key take away

Apremilast is equally effective as Methotrexate in addressing moderate-to-severe palmoplantar psoriasis, with the added benefit of being better tolerated.

Background

This randomized clinical trial sought to determine the tolerability and effectiveness of Apremilast and Methotrexate in individuals suffering from palmoplantar psoriasis.

Method

In this parallel-group, prospective, open-label study, participants (aged between 18 and 65 years) battling palmoplantar psoriasis were randomly allocated into two groups: Methotrexate (n = 19) or Apremilast (n = 22) for a duration of sixteen weeks. From week 0 to week sixteen, the decrease in the modified Palmoplantar Psoriasis Area and Severity Index (mPPPASI) score was the key effectiveness outcome.

Secondary outcomes encompassed: (a) Proportion of people achieving mPPPASI75 (75% drop in mPPPASI score) at the end of sixteen weeks, (b) Proportion of people achieving a Static Physician Global Assessment score of 0 (clear) or 1 (almost clear), and (c) Proportion of people exhibiting at least a five-point decrease in the Dermatology Life Quality Index (DLQI) from the baseline.

Result

While there was a noteworthy decline in the m-PPPASI score within each group from week 0 to week 16, the difference in the score reduction between the two groups at 16 weeks was not statistically significant, as depicted in Figure 1:

Comparable results were witnessed with the secondary efficacy parameters. In the Methotrexate group, 24 adverse events were recorded, including abnormal liver function tests in three subjects. In the Apremilast arm, 19 adverse events were documented, with two subjects experiencing upper respiratory tract infections.

Conclusion

Apremilast demonstrated efficiency comparable to Methotrexate in tackling moderate-to-severe palmoplantar psoriasis with improved tolerability. Therefore, it could be considered as an alternative to established drugs for palmoplantar psoriasis-affected people who do not respond to or tolerate other medications.

Source:

Indian Journal of Pharmacology

Article:

Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial

Authors:

Wagh M et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: